Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Questions and Answers about the ACCORD Trial — Updated March 14, 2010

Effects of Intensive Blood Pressure and Combination Lipid Therapies in Type 2 Diabetes
Announcements — March 14, 2008

• New Release: Landmark ACCORD Trial Finds Intensive Blood Pressure and Combination Lipid Therapies do not Reduce Combined Cardiovascular Events in Adults with Diabetes — March 14, 2010
• NEJM: Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus — March 14, 2010
• NEJM: Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus —March 14, 2010

NEJM Editorials and Perspective:

• ACCORD and Risk-Factor Control in Type 2 Diabetes — March 14, 2010

Effects of Intensive Glucose Lowering in Type 2 Diabetes Announcements — June 6, 2008

• New Release: ACCORD Clinical Trial Publishes Results—
  A Therapeutic Strategy Targeting Blood Sugar to Near-Normal Levels Does Not Reduce Cardiovascular Events But Increases Mortality in Persons with Diabetes at High Risk
• NEJM: Effects of Intensive Glucose Lowering in Type 2 Diabetes

NEJM Editorials and Perspective:

• Intensive Glycemic Control in the ACCORD and ADVANCE Trials, Robert G. Dluhy, M.D., and Graham T. McMahon, M.D., M.M.Sc.
• Glycemic Targets and Cardiovascular Disease, William T. Cefalu, M.D.
• Redefining Quality - Implications of Recent Clinical Trials, Harlan M. Krumholz, M.D., and Thomas H. Lee, M.D.

ACCORD Blood Sugar Strategy Announcement — February 6, 2008

• Sample Letter To Participants
• News Conference
• News Release
• Prepared Remarks, 540 K
  • Elizabeth G. Nabel, MD
  • William T. Friedewald, MD
  • Hertzel C. Gerstein, MD, MSc FRCPC
  • Judith Fradkin, MD
• The Full News Conference
  • Audio, WAV file, 56.7 MB
  • Transcript, 132 K

ACCORD Study Web Site

• List of ACCORD Clinical Center Networks and Network Sites

Last updated: March 22, 2011